<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Allergan Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/allergan-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABT) Abbott Expands Ophthalmic Portfolio</title>
		<link>http://www.stockbloghub.com/2009/09/03/abt-abbott-expands-ophthalmic-portfolio/14341</link>
		<comments>http://www.stockbloghub.com/2009/09/03/abt-abbott-expands-ophthalmic-portfolio/14341#comments</comments>
		<pubDate>Thu, 03 Sep 2009 20:59:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14341</guid>
		<description><![CDATA[Abbott (ABT) yesterday entered into a definitive agreement whereby it will acquire Visiogen, Inc., a privately-held company, for $400 million in cash. Visiogen is focused on the development of innovative products for cataract and refractive patients. The deal will provide Abbott with access to Visiogen’s next-generation accommodating intraocular lens (IOL) technology, which helps address presbyopia in cataract patients. Visiogen’s first commercial application, Synchrony, is currently available in Europe and under Food and Drug Administration (FDA) review in the U.S. Synchrony is designed to deliver improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity. This deal is in-line with Abbott’s goal of strengthening its ophthalmic portfolio. As a reminder, Abbott entered the ophthalmology market earlier this year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/abt-abbott-expands-ophthalmic-portfolio/14341/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISTA) ISTA Pharmaceuticals&#8217;s Eye Drug Shows Success</title>
		<link>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559</link>
		<comments>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559#comments</comments>
		<pubDate>Thu, 27 Aug 2009 19:51:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13559</guid>
		<description><![CDATA[ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post cataract surgery. The drug was also successful in eliminating eye pain one day following surgery. No serious adverse events were observed and the safety profile appeared to be consistent with the company’s twice a day Xibrom version, which has already hit the market. The U.S. marketing rights to Xibrom, which is used for the treatment of ocular inflammation following cataract surgery, were acquired by ISTA in 2002 and the product was launched in the U.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Receives FDA Warning</title>
		<link>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287</link>
		<comments>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:23:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13287</guid>
		<description><![CDATA[On Aug. 21, Allergan, Inc. (AGN) received a warning letter from the U.S. Food and Drug Administration’s (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) regarding a misleading advertisement used by the company for its acne treatment Aczone Gel, 5%. Aczone is a topical gel formulation, which is approved in the U.S. and Canada for the treatment of acne vulgaris in patients 12 years and older. Allergan acquired the product in July 2008 from QLT Inc. for $150 million in order to bolster its skin care franchise. In the warning letter, the FDA stated that the claims made by the company in the advertisement are a misrepresentation of the clinical results. According to the agency, the benefits of Aczone have been overstated. In the advertisement, Allergan claims that Aczone ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

